Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 5/2014

01-06-2014 | Original Article

Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis

Authors: Axel Wetter, Christine Lipponer, Felix Nensa, Philipp Heusch, Herbert Rübben, Thomas W. Schlosser, Thorsten D. Pöppel, Thomas C. Lauenstein, James Nagarajah

Published in: Annals of Nuclear Medicine | Issue 5/2014

Login to get access

Abstract

Objective

To quantitatively analyze bone metastases from prostate cancer and correlate the apparent diffusion coefficients (ADCs) and standardized uptake values (SUVs).

Methods

Fifty-five patients with biopsy-proven prostate cancer or suspected recurrent prostate cancer were examined with simultaneous [18F] choline Positron emission tomography (PET)/MRI at 3 T. In 11 patients, thirty-two PET-positive bone lesions could be identified that were located in the field-of-view of the Diffusion weighted imaging-sequence. Region-of-interest and volume-of-interest analyses were performed to measure the mean and minimal ADCs and to assess maximum and mean SUVs of every bone lesion. Correlations between maximum and mean SUVs and mean and minimal ADCs were calculated.

Results

The SUVmax of all lesions was 5.5 ± 3.1 (mean ± SD). The SUVmean was 1.8 ± 0.9. The mean ADC (ADCmean) of all lesions was 0.67 ± 0.13 × 10−3 mm2/s. The minimal ADC (ADCmin) of all lesions was 0.56 ± 0.14 × 10−3 mm2/s. There was a moderate but significant inverse correlation of SUVmax vs. ADCmean with a correlation coefficient of −0.4 (p = 0.02). There was also a significant inverse correlation of SUVmax vs. ADCmin with r = −0.41 (p = 0.02).

Conclusion

Our initial results demonstrate a moderate but significant inverse correlation between increased choline metabolism and ADC values of bone metastases from prostate cancer. Further research on a multimodality approach using simultaneous PET/MRI in bone metastasis of prostate cancer seems to be justified.
Literature
1.
Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis. 2011;14(2):177–83.PubMedCrossRef
2.
Kamiya N, Suzuki H, Endo T, et al. Clinical usefulness of bone markers in prostate cancer with bone metastasis. Int J Urol. 2012;19(11):968–79.PubMedCrossRef
3.
Koh DM, Sohaib A. Diffusion-weighted imaging of the male pelvis. Radiol Clin North Am. 2012;50(6):1127–44.PubMedCrossRef
4.
Eiber M, Holzapfel K, Ganter C, et al. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging. 2011;33(5):1160–70.PubMedCrossRef
5.
Kjölhede H, Ahlgren G, Almquist H, et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int. 2012;110(10):1501–6.PubMedCrossRef
6.
Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M. Rachinsky I.18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15(1):45–55 Review.PubMedCrossRef
7.
Beer AJ, Eiber M, Souvatzoglou M, et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol. 2011;13(2):352–61.PubMedCrossRef
8.
Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53(6):928–38 Review.PubMedCrossRef
9.
Martinez-Möller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520–6.PubMedCrossRef
10.
11.
Matsushima N, Maeda M, Umino M, Suzawa N, Yamada T, Takeda K. Relation between FDG uptake and apparent diffusion coefficients in glioma and malignant lymphoma. Ann Nucl Med. 2012;26(3):262–71.PubMedCrossRef
12.
Regier M, Derlin T, Schwarz D, et al. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)? Eur J Radiol. 2012;81(10):2913–8.PubMedCrossRef
13.
Wong CS, Gong N, Chu YC, et al. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV. Eur J Radiol. 2012;81(9):2122–6.PubMedCrossRef
14.
Ho KC, Lin G, Wang JJ, Lai CH, Chang CJ, Yen TC. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging. 2009;36(2):200–8.PubMedCrossRef
15.
Gong NJ, Wong CS, Chu YC, Gu J. Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography. NMR Biomed. 2013;26(2):185–92.PubMedCrossRef
16.
Park SH, Moon WK, Cho N, et al. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol. 2012;22(1):18–25.PubMedCrossRef
17.
Lambrecht M, Deroose C, Roels S, et al. The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol. 2010;49(7):956–63.PubMedCrossRef
18.
Buchbender C, Hartung-Knemeyer V, Heusch P, et al. Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system? Eur J Radiol. 2013;82(2):380–4.PubMedCrossRef
19.
Heusch P, Buchbender C, Köhler J et al. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in Hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results. Rofo. 2013;185(11):1056–62.
20.
21.
Reischauer C, Froehlich JM, Koh DM, et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps–initial observations. Radiology. 2010;257(2):523–31.PubMedCrossRef
22.
Lee KC, Sud S, Meyer CR, et al. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res. 2007;67(8):3524–8.PubMedCrossRef
23.
Lee KC, Bradley DA, Hussain M, et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia. 2007;9(12):1003–11.PubMedCentralPubMedCrossRef
24.
Wetter A, Lipponer C, Nensa F, et al. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur J Nucl Med Mol Imaging. 2014;41(1):79–88.PubMedCrossRef
25.
Souvatzoglou M, Eiber M, Takei T, et al. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(10):1486–99.PubMedCrossRef
Metadata
Title
Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis
Authors
Axel Wetter
Christine Lipponer
Felix Nensa
Philipp Heusch
Herbert Rübben
Thomas W. Schlosser
Thorsten D. Pöppel
Thomas C. Lauenstein
James Nagarajah
Publication date
01-06-2014
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 5/2014
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-014-0825-x

Other articles of this Issue 5/2014

Annals of Nuclear Medicine 5/2014 Go to the issue

Original Article

Tc-99m depreotide SPECT/CT for lymph node staging of non-small-cell lung cancer

Case Report

Radioiodine uptake in a renal cyst mimicking a metastasis in a patient affected by differentiated thyroid cancer: case report and review of the literature

Short Communication

Lymphoscintigraphy in early-stage non-small cell lung cancer with technetium-99m nanocolloids and hybrid SPECT/CT: a pilot project

Others

Japanese consensus guidelines for pediatric nuclear medicine

Original Article

Characteristics and trends of research on positron emission tomography: a bibliometric analysis, 2002–2012

Original Article

Evaluation of analytical reconstruction with a new gap-filling method in comparison to iterative reconstruction in []-raclopride PET studies